Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
IBRX.US
id: 716, Created by Stan Vick Chase, Scout
Join ImmunityBio (IBRX) Case to Fight Your Losses
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
On May 11, 2023, ImmunityBio (IBRX) disclosed that it received a complete response letter from the FDA regarding its Biologics License Application (BLA) for its product candidate Anktiva (N-803) indicating that the FDA has determined that it cannot approve the BLA in its present form based on “deficiencies related to the FDA’s pre-license inspection of the Company’s third-party contract manufacturing organizations” and that “satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved.”
On this news, $IBRX fell over 55% and lost around $1.5 billion of its market capitalization, seriously damaging investors.
Taking all facts and market reaction into account, Investors may have reasons to suspect ImmunityBio and its Leaders of misleading and failing to disclose correct information about the manufacturing conditions of its product candidate which led to investment losses to shareholders.
Alleged Offence
Misleading Statements,
Failure to Disclose,
Negligence,
Omissions
Suspected Party
Directors,
Management,
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
11 May 2023